Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RECQL | P46063 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Water SCHEMBL28290120 | 0.97 | RECQL (0.33) | RECQL | |
| SCHEMBL6701254 | 0.83 | RECQL (0.34) | RECQLTSHRPOLB | |
| SCHEMBL20991799 | 0.80 | — | — | |
| SCHEMBL19503457 | 0.80 | — | — | |
| SCHEMBL14463785 | 0.79 | RECQL (0.32) | RECQL | |
| SCHEMBL22214033 | 0.79 | RECQL (0.36) | RECQLTSHRPOLB | |
| SCHEMBL12533301 | 0.79 | — | — | |
| SCHEMBL9647862 | 0.79 | RECQL (0.32) | RECQL | |
| SCHEMBL4758990 | 0.76 | RECQL (0.39) | RECQLTSHRPOLB | |
| SCHEMBL22393884 | 0.75 | RECQL (0.34) | RECQLTSHRPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 108 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240239811-A1 | 5-(5-(PIPERIDIN-4-YL)THIENO[3,2-C]PYRAZOL-2-YL]INDAZOLE DERIVATIVES AND RELATED COMPOUNDS AS MODULATORS FOR SPLICING NUCLEIC ACIDS AND FOR THE T | REMIX THERAPEUTICS INC. | 2024-07-18 | — | — | US | disclosed |
| EP-4320665-A1 | A SOLUTION OF ALKYLATED PIPERIDINAMINE- AND PIPERIDINAMINIUM-DERIVATES FOR THE PRODUCTION OF A PURIFIED SOLUTION OF TEMPO-DERIVATES FOR THE USE AS ELECTROLYTE IN REDOX-FLOW CELLS | BASF SE (DE) | 2024-02-14 | — | — | EP | disclosed |
| WO-2023227697-A1 | NEW DERIVATIVES FOR TREATING TRPM3 MEDIATED DISORDERS | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2023-11-30 | — | — | WO | disclosed |
| WO-2023230540-A2 | INDAZOLE DERIVATIVES FOR TREATING TRPM3-MEDIATED DISORDERS | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2023-11-30 | — | — | WO | disclosed |
| WO-2023230542-A2 | PYRAZOLO[1,5-a]PYRIDINE DERIVATIVES FOR TREATING TRPM3-MEDIATED DISORDERS | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2023-11-30 | — | — | WO | disclosed |
| US-20230365566-A1 | HETEROCYCLIC AMIDES AND THEIR USE FOR MODULATING SPLICING | REMIX THERAPEUTICS INC. | 2023-11-16 | — | — | US | disclosed |
| US-20230365526-A1 | PYRIDAZINE DERIVATIVES FOR MODULATING NUCLEIC ACID SPLICING | REMIX THERAPEUTICS INC (US) | 2023-11-16 | — | — | US | disclosed |
| US-20230365530-A1 | QUINAZOLINE-2,4-DIAMINE DERIVATIVE AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING CANCER COMPRISING SAME AS ACTIVE INGREDIENT | OMIC SMAP INC. (KR) | 2023-11-16 | — | — | US | disclosed |
| US-20230365530-A1 | QUINAZOLINE-2,4-DIAMINE DERIVATIVE AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING CANCER COMPRISING SAME AS ACTIVE INGREDIENT | OMIC SMAP INC. (KR) | 2023-11-16 | — | — | US | disclosed |
| US-11672799-B2 | 1,4-disubstituted pyridazine quinolne analogs there of and methods for treating SMN-deficiency-related conditions | NOVARTIS AG (CH) | 2023-06-13 | — | — | US | disclosed |
| US-7714013-B2 | Azole derivatives and fused bicyclic azole derivatives as therapeutic agents | TRANSTECH PHARMA, INC. (US) | 2010-05-11 | — | — | US | disclosed |
| US-20090306257-A1 | Stabilizer System for Halogenated Polymers | CATENA ADDITIVES GMBH & CO. KG (DE) | 2009-12-10 | — | — | US | disclosed |
| US-20090176988-A1 | Preparation and Use of Magnesium Amides | LUDWIG-MAXIMILIANS-UNIVERSITAT MUENCHEN (DE) | 2009-07-09 | — | — | US | disclosed |
| US-20090176988-A1 | Preparation and Use of Magnesium Amides | LUDWIG-MAXIMILIANS-UNIVERSITAT MUENCHEN (DE) | 2009-07-09 | — | — | US | disclosed |
| US-20090035302-A1 | Rage Antagonists As Agents To Reverse Amyloidosis And Diseases Associated Therewith | TRANSTECH PHARMA, INC. (US) | 2009-02-05 | — | — | US | disclosed |
| EP-1882724-B1 | Ink composition, inkjet recording method, printed material, and process for producing lithographic printing plate | FUJIFILM CORP (JP) | 2008-12-03 | — | — | EP | disclosed |
| US-7361678-B2 | Azole derivatives and fused bicyclic azole derivatives as therapeutic agents | TRANSTECH PHARMA, INC. (US) | 2008-04-22 | — | — | US | disclosed |
| EP-1882724-A1 | Ink composition, inkjet recording method, printed material, and process for producing lithographic printing plate | FUJIFILM Corporation (JP) | 2008-01-30 | — | — | EP | disclosed |
| US-20070213347-A1 | Azole derivatives and fused bicyclic azole derivatives as therapeutic agents | TRANSTECH PHARMA (US) | 2007-09-13 | — | — | US | disclosed |
| US-20070021386-A1 | Azole derivatives and fused bicyclic azole derivatives as therapeutic agents | TRANSTECH PHARMA (US) | 2007-01-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230365566-A1 | HETEROCYCLIC AMIDES AND THEIR USE FOR MODULATING SPLICING | RBM17, HNRNPA1, HNRNPAB | RECQL 1076/4885TSHR 3876/4885POLB 319/4885 |
| US-20090035302-A1 | Rage Antagonists As Agents To Reverse Amyloidosis And Diseases Associated Therewith | AGER, APP, BACE1 | RECQL 3127/4885TSHR 3214/4885POLB 4506/4885 |
| US-20070021386-A1 | Azole derivatives and fused bicyclic azole derivatives as therapeutic agents | AGER, S100A4, S100B | RECQL 4688/4885TSHR 3767/4885POLB 4665/4885 |
| US-11672799-B2 | 1,4-disubstituted pyridazine quinolne analogs there of and methods for treating SMN-deficiency-related conditions | SMN1; SMN2, CLN6, PMP22 | RECQL 78/4885TSHR 4785/4885POLB 735/4885 |
| US-20230365526-A1 | PYRIDAZINE DERIVATIVES FOR MODULATING NUCLEIC ACID SPLICING | SNRPA, RBM17, SNRPB2 | RECQL 532/4885TSHR 3522/4885POLB 189/4885 |
| US-20090176988-A1 | Preparation and Use of Magnesium Amides | MLX, GLRX3, SFXN3 | RECQL 2772/4885TSHR 49/4885POLB 2065/4885 |
| US-20240239811-A1 | 5-(5-(PIPERIDIN-4-YL)THIENO[3,2-C]PYRAZOL-2-YL]INDAZOLE DERIVATIVES AND RELATED COMPOUNDS AS MODULATORS FOR SPLICING NUCLEIC ACIDS AND FOR THE T | HNRNPAB, HNRNPC, HNRNPA1 | RECQL 333/4885TSHR 1585/4885POLB 71/4885 |
| US-20230365530-A1 | QUINAZOLINE-2,4-DIAMINE DERIVATIVE AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING CANCER COMPRISING SAME AS ACTIVE INGREDIENT | EHMT2, EHMT1, HNMT | RECQL 491/4885TSHR 4814/4885POLB 1753/4885 |
| US-20070213347-A1 | Azole derivatives and fused bicyclic azole derivatives as therapeutic agents | AGER, S100A4, S100B | RECQL 4688/4885TSHR 3767/4885POLB 4665/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.